This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Available from: [link] About the author Cliff Brass, MD PhD FAASLD, Chief Medical Officer at Resolution Therapeutics Cliff Brass is an expert in clinicaldevelopment with special expertise in liver disease and over 25 years of experience in pharma. Reference 1 Brennan P et al., J Hep, 2024 (EASL ILC 2024 Abstract #LBP-007).
Roy Baynes, Senior Vice President and Head of Global ClinicalDevelopment, Chief Medical Officer at MSD ResearchLaboratories, said: “HRD is an important biomarker of advanced ovarian cancer that can inform how physicians in the EU treat this aggressive type of cancer. months versus 35.3 months with bevacizumab.
“While the treatment landscape has evolved, an unmet need remains for appropriate patients newly diagnosed with certain types of advanced urothelial carcinoma who are not eligible for platinum-containing chemotherapy,” said Dr. Scot Ebbinghaus, vice president, clinicalresearch, Merck ResearchLaboratories. “We
About Loxo Oncology at Lilly Loxo Oncology at Lilly was created in December 2019, combining the Lilly ResearchLaboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. For more information, please visit www.kumquatbiosciences.com. Source link: [link] nvestor.lilly.com/.
Previously, Baffa was Therapeutic Area Head of Oncology, Global ClinicalDevelopment for Shire. The company also announced the addition of Robin Patel to its clinical and scientific advisory board. Additionally, Raffaele Baffa was named chief medical officer of Ziopharm.
We are excited to embark on this partnership with Boehringer Ingelheim to identify potential therapeutic candidates and advance them to clinicaldevelopment in order to help improve the lives of those affected by this serious mental health condition.”. The Lieber Institute for Brain Development. Weinberger, M.D.,
Most importantly, we are continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinicaldevelopment. These manufactured antibodies have been developed and manufactured by Eli Lilly and Company ’s Lilly ResearchLaboratories in a partnership with AbCellera.
Cadavid will be responsible for the strategy, direction and execution of the company’s clinicaldevelopment programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinicaldevelopment group. He spent 27 years at Merck & Co.
“We are pleased to offer two potential new treatment options with KEYTRUDA for patients in Japan based on compelling data from our clinical trial program,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
“There is a real need to advance new treatment options for triple-negative breast cancer, an aggressive form of the disease,” said Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories, in July 2020.
Loxo Oncology at Lilly was created in December 2019, combining the Lilly ResearchLaboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. Our approach centers on creating new oncology medicines that unequivocally work early in clinicaldevelopment and will matter to patients.
Anderson most recently served as Vice President and Chief Scientific Officer for Bacterial Research and Hospital within the Vaccine R&D organization. Prior to Pfizer, Dr. Anderson worked at Merck ResearchLaboratories where she founded its prokaryotic bio-combinatorial engineering laboratory and initiated a bacterial vaccine program.
We strongly believe in the results of the PROpel trial, which demonstrated the clinically meaningful benefit for this combination in a broad population of patients regardless of biomarker status.”
Loxo Oncology at Lilly was created in December 2019, combining the Lilly ResearchLaboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. Our approach centers on creating new oncology medicines that unequivocally work early in clinicaldevelopment and will matter to patients.
Baynes, head of Global ClinicalDevelopment (GCD) and Chief Medical Officer, Merck ResearchLaboratories (MRL), will be retiring from Merck in July. Li, president, Merck ResearchLaboratories, until his retirement. He also led the expansion of Merck’s research and development in China and Japan. “It
“We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings and plan to provide updates when appropriate,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
It is very clear that in this study, the addition of ipilimumab did not add clinical benefit but did add toxicity. Merck and Eisai are committed to working together to continue to explore the potential of the KEYTRUDA plus LENVIMA combination, particularly in areas of great unmet need such as renal cell carcinoma.”. “We
Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1. “In Perlmutter, President, Merck ResearchLaboratories. “We
“These highly anticipated event-free survival results in this TNBC population build upon earlier findings from the KEYNOTE-522 trial and further support the potential use of KEYTRUDA in these patients,” said Dr. Vicki Goodman, vice president, clinicalresearch, Merck ResearchLaboratories.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinicaldevelopment program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21.
“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories. “If
“Since its first approval in renal cell carcinoma nearly two years ago, KEYTRUDA has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
Eliav Barr, senior vice president, head of global clinicaldevelopment and chief medical officer, Merck ResearchLaboratories, said, “It is imperative that we create new ways to treat advanced cancers and help improve patient outcomes by building on the current standard of care.
“We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen for islatravir using a subdermal implant,” said Dr. Joan Butterton, vice president, global clinicaldevelopment, infectious diseases, Merck ResearchLaboratories. “We
“The FDA’s acceptance of our application adds to our momentum of advancing new treatment options to address the most challenging cancers facing women,” said Dr. Scot Ebbinghaus, vice president, clinicalresearch, Merck ResearchLaboratories. About KEYNOTE-158.
Merck is continuing to study KEYTRUDA, in combination or as monotherapy, as well as other investigational products across multiple settings and stages of RCC including adjuvant and advanced or metastatic disease through our broad clinicaldevelopment program, which includes over 20 clinical studies and more than 4,000 patients.
That’s why we set out to develop a conjugate vaccine that includes pneumococcal serotypes that pose the greatest threat and elicits a strong immune response to each serotype covered,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
“There remains a significant unmet need for patients diagnosed with advanced prostate cancer, who have a poor prognosis after not responding to initial therapy,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
Gilead Lores, and Merck, known as MSD outside the United States and Canada, moment blazoned the launch of a Phase 2 clinical study assessing an investigational formerly-daily oral combination treatment authority of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral remedy.
All clinical studies provide important learnings to help us in the fight against HIV, and we are grateful to the patients and investigators for their contributions.”. mg daily (DOR/ISL) in HIV-1 virologically suppressed participants.
We are delighted that PREVYMIS is now approved to help prevent CMV disease in adult kidney transplant patients at high risk,” said Dr. Elizabeth Rhee, vice president, global clinicaldevelopment, Merck ResearchLaboratories. “At Source link: [link]
We strongly believe in the results of the PROpel trial, which demonstrated a clinically meaningful benefit for this combination in a broad population of patients regardless of biomarker status.”
“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
“Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinicalresearch, Merck ResearchLaboratories. Importantly, this treatment regimen are often utilized in combination with different chemotherapy agents.
“This announcement reflects another important regulatory milestone in the development of this medicine,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
As part of our commitment to understanding the potential for our HIV medicines in a broad range of patients, we focused on the enrollment of diverse patient populations at risk for HIV, including women, who have one of the highest unmet needs in HIV prevention.”.
Rubin, senior vice president, global clinicaldevelopment, Merck ResearchLaboratories. “Patients with stage III and IV melanoma can be at high risk of having their cancer recur or metastasize to other sites,” said Dr. Eric H.
Joerg Koglin, vice chairman, Global ClinicalDevelopment and Therapeutic Area Head, Cardiovascular for Merck ResearchLaboratories. The inauguration of the Phase 3 VICTOR study reflects our commitment to chancing fresh options for a habitual heart failure condition that affects further than 3 million people in theU.S.
We are pleased to offer a meaningful new treatment option for appropriate patients with symptomatic chronic heart failure,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
“There have been few advances in improving survival outcomes in the first-line treatment setting for esophageal cancer over the last three decades,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories. “We
This expands the use of KEYTRUDA-based regimens to more patients with advanced urothelial carcinoma and demonstrates the value of collaboration in creating new combination approaches for patients in need of more options.”
Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories. Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content